Optics and Photonics Group, Faculty of Engineering, University of Nottingham, NG7 2RD, UK.
Analyst. 2020 Jul 7;145(13):4504-4511. doi: 10.1039/d0an00434k. Epub 2020 May 15.
Dabrafenib is one of the most widely used of the new generation of targeted anti-cancer drugs. However, its therapeutic window varies for different patients and so there is an unmet need for methods to monitor the dose of drug which the patient receives and at the specific site where it acts. In the case of cancers, it is critical to measure the concentration of drug not just in the bloodstream overall, but in or near tumours, as these will not be the same over multiple time periods. A novel sensor based on an optical fibre long period grating (LPG) modified with a molecular imprinted polymer (MIP) has been developed with the ultimate aim of achieving minimally invasive measurements of Dabrafenib at the tumour site. A molecularly imprinted polymer specific for Dabrafenib was coated on a methacryloylalkoxysilane-functionalised optical fibre long period grating. In vitro experimental results demonstrate that the Dabrafenib sensitivity is 15.2 pm (μg mL) (R = 0.993) with a limit of detection (LoD) of 74.4 μg mL in serum solution. Moreover, the proposed sensor shows selective response to Dabrafenib over structurally similar 2-Aminoquinoline.
达布拉非尼是新一代靶向抗癌药物中应用最广泛的药物之一。然而，不同患者的治疗窗不同，因此需要一种方法来监测患者接受的药物剂量和药物作用的特定部位。在癌症的情况下，测量药物浓度不仅在整个血液中很重要，而且在肿瘤内或附近也很重要，因为在多个时间段内，这些浓度不会相同。已经开发出一种基于光纤长周期光栅 (LPG) 的新型传感器，该传感器用分子印迹聚合物 (MIP) 进行了修饰，其最终目的是实现对肿瘤部位达布拉非尼的微创测量。在体外实验中，结果表明，达布拉非尼的灵敏度为 15.2 pm（μg mL）（R = 0.993），在血清溶液中的检测限（LoD）为 74.4 μg mL。此外，与结构相似的 2-氨基喹啉相比，该传感器对达布拉非尼具有选择性响应。
